Small study checks early bacteria-killing power of common MAC drug
NCT ID NCT04287049
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study looked at how well the antibiotic azithromycin kills Mycobacterium avium complex (MAC) bacteria in the lungs during the first 14 days of treatment. Ten adults with MAC lung disease took azithromycin daily, and researchers measured bacterial levels in their sputum. The goal was to understand early drug activity, not to test a cure or new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYCOBACTERIUM AVIUM COMPLEX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21205, United States